New cell therapy aims to tame painful skin disease
Disease control
Ongoing
This early-stage study is testing the safety of SBT777101, a new treatment for hidradenitis suppurativa (HS). The therapy uses a patient's own immune cells, modified to target and calm inflammation in affected skin. Researchers will give single doses to 24 adults with moderate-to…
Phase: PHASE1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC